Cost Analysis of Percutaneous Segmentectomy Versus Chemoembolisation and Radioembolisation in Hepatocellular Carcinoma: A Retrospective Multicentre Cohort Study.
Pierleone Lucatelli, Laura Crocetti, Renato Argirò, Roberto Iezzi, Chiara Reale, Valeria Grillo, Tetyana Shchipska, Alessandro Maresca, Marcello Lippi, Elena Bozzi, Roberto Cioni, Matteo Madonna, Marta Pignataro, Mario Corona, Valeria Panebianco, Carlo Catalano, Andrea Gallivanone, Nicolò Schiesaro, Agnese Bonino, Vittorio Pedicini, Andrea Laghi, Ezio Lanza
{"title":"Cost Analysis of Percutaneous Segmentectomy Versus Chemoembolisation and Radioembolisation in Hepatocellular Carcinoma: A Retrospective Multicentre Cohort Study.","authors":"Pierleone Lucatelli, Laura Crocetti, Renato Argirò, Roberto Iezzi, Chiara Reale, Valeria Grillo, Tetyana Shchipska, Alessandro Maresca, Marcello Lippi, Elena Bozzi, Roberto Cioni, Matteo Madonna, Marta Pignataro, Mario Corona, Valeria Panebianco, Carlo Catalano, Andrea Gallivanone, Nicolò Schiesaro, Agnese Bonino, Vittorio Pedicini, Andrea Laghi, Ezio Lanza","doi":"10.1007/s00270-026-04647-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To compare the costs of percutaneous segmentectomy, a single-session combination of transarterial embolisation and microwave ablation, against chemoembolisation and radioembolisation for hepatocellular carcinoma.</p><p><strong>Materials and methods: </strong>Retrospective cost analysis of 66 patients treated with percutaneous segmentectomy at five Italian centres, using bottom-up micro-costing. Comparator costs were derived from published Italian per-session costs multiplied by mean sessions per patient, and survival from published curves. A partitioned survival model estimated life-years and incremental net monetary benefit at 50,000 euros per life-year.</p><p><strong>Results: </strong>Procedural cost per treated patient was 6331 euros for percutaneous segmentectomy, 9792 euros for chemoembolisation (mean 2.94 sessions), and 21,673 euros for radioembolisation (1.52 sessions). At 24 months, percutaneous segmentectomy had lower total cost and a small life-year deficit (incremental cost-effectiveness ratio approximately 70,800 euros per life-year versus chemoembolisation and 57,500 versus radioembolisation, both above threshold). This life-year-adjusted advantage reversed versus chemoembolisation, and became neutral versus radioembolisation, in a worst-case sensitivity analysis, and reversed against both when transplantation costs for the eight transplanted patients (19%) were attributed to percutaneous segmentectomy alone.</p><p><strong>Conclusion: </strong>In this exploratory analysis, percutaneous segmentectomy appeared to have a lower procedural cost per treated patient than chemoembolisation and radioembolisation, mainly because it is delivered in a single session. However, because costing routes, cohorts, and survival sources were not equivalent and the life-year-adjusted comparison was not robust, no formal cost superiority can be established. These hypothesis-generating findings require confirmation in prospective, matched studies.</p><p><strong>Level of evidence: </strong>Level 4, Retrospective Cohort Study with Historical Comparators.</p>","PeriodicalId":9591,"journal":{"name":"CardioVascular and Interventional Radiology","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CardioVascular and Interventional Radiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00270-026-04647-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: To compare the costs of percutaneous segmentectomy, a single-session combination of transarterial embolisation and microwave ablation, against chemoembolisation and radioembolisation for hepatocellular carcinoma.
Materials and methods: Retrospective cost analysis of 66 patients treated with percutaneous segmentectomy at five Italian centres, using bottom-up micro-costing. Comparator costs were derived from published Italian per-session costs multiplied by mean sessions per patient, and survival from published curves. A partitioned survival model estimated life-years and incremental net monetary benefit at 50,000 euros per life-year.
Results: Procedural cost per treated patient was 6331 euros for percutaneous segmentectomy, 9792 euros for chemoembolisation (mean 2.94 sessions), and 21,673 euros for radioembolisation (1.52 sessions). At 24 months, percutaneous segmentectomy had lower total cost and a small life-year deficit (incremental cost-effectiveness ratio approximately 70,800 euros per life-year versus chemoembolisation and 57,500 versus radioembolisation, both above threshold). This life-year-adjusted advantage reversed versus chemoembolisation, and became neutral versus radioembolisation, in a worst-case sensitivity analysis, and reversed against both when transplantation costs for the eight transplanted patients (19%) were attributed to percutaneous segmentectomy alone.
Conclusion: In this exploratory analysis, percutaneous segmentectomy appeared to have a lower procedural cost per treated patient than chemoembolisation and radioembolisation, mainly because it is delivered in a single session. However, because costing routes, cohorts, and survival sources were not equivalent and the life-year-adjusted comparison was not robust, no formal cost superiority can be established. These hypothesis-generating findings require confirmation in prospective, matched studies.
Level of evidence: Level 4, Retrospective Cohort Study with Historical Comparators.
期刊介绍：
CardioVascular and Interventional Radiology (CVIR) is the official journal of the Cardiovascular and Interventional Radiological Society of Europe, and is also the official organ of a number of additional distinguished national and international interventional radiological societies. CVIR publishes double blinded peer-reviewed original research work including clinical and laboratory investigations, technical notes, case reports, works in progress, and letters to the editor, as well as review articles, pictorial essays, editorials, and special invited submissions in the field of vascular and interventional radiology. Beside the communication of the latest research results in this field, it is also the aim of CVIR to support continuous medical education. Articles that are accepted for publication are done so with the understanding that they, or their substantive contents, have not been and will not be submitted to any other publication.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
